Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.

Ann Hematol 2016 Mar 12;95(4):563-73. Epub 2016 Jan 12.

The University of Arizona Cancer Center, Tucson, AZ, USA.

Effective new treatments are now available for patients with hematologic malignancies. However, their propensity to cause tumor lysis syndrome (TLS) has not been systematically examined. A literature search identified published Phase I-III clinical trials of monoclonal antibodies (otlertuzumab, brentuximab, obinutuzumab, ibritumomab, ofatumumab); tyrosine kinase inhibitors (alvocidib [flavopiridol], dinaciclib, ibrutinib, nilotinib, dasatinib, idelalisib, venetoclax [ABT-199]); proteasome inhibitors (oprozomib, carfilzomib); chimeric antigen receptor (CAR) T cells; and the proapoptotic agent lenalidomide. Abstracts from major congresses were also reviewed. Idelalisib and ofatumumab had no reported TLS. TLS incidence was ≤5 % with brentuximab vedotin (for anaplastic large-cell lymphoma), carfilzomib and lenalidomide (for multiple myeloma), dasatinib (for acute lymphoblastic leukemia), and oprozomib (for various hematologic malignancies). TLS incidences were 8.3 and 8.9 % in two trials of venetoclax (for chronic lymphocytic leukemia [CLL]) and 10 % in trials of CAR T cells (for B-cell malignancies) and obinutuzumab (for non-Hodgkin lymphoma). TLS rates of 15 % with dinaciclib and 42 and 53 % with alvocidib (with sequential cytarabine and mitoxantrone) were seen in trials of acute leukemias. TLS mitigation was employed routinely in clinical trials of alvocidib and lenalidomide. However, TLS mitigation strategies were not mentioned or stated only in general terms for many studies of other agents. The risk of TLS persists in the current era of novel and targeted therapy for hematologic malignancies and was seen to some extent with most agents. Our findings underscore the importance of continued awareness, risk assessment, and prevention to reduce this serious potential complication of effective anticancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2585-7DOI Listing
March 2016
22 Reads

Publication Analysis

Top Keywords

hematologic malignancies
16
patients hematologic
8
novel targeted
8
tls
8
car cells
8
tls mitigation
8
era novel
8
clinical trials
8
tumor lysis
8
lysis syndrome
8
trials
5
malignancies
5
venetoclax chronic
4
89 % trials
4
trials venetoclax
4
incidences 89 %
4
tls incidences
4
lymphoblastic leukemia
4
leukemia oprozomib
4
oprozomib hematologic
4

References

(Supplied by CrossRef)

P Bose et al.
J Clin Pharm Ther 2011

SC Howard et al.
N Engl J Med 2011

FP Wilson et al.
Adv Chronic Kidney Dis 2014

MS Cairo et al.
Br J Haematol 2010

TI Mughal et al.
Cancer Treat Rev 2010

JE Karp et al.
Leuk Res 2010

JF Seymour et al.
J Clin Oncol 2013

S Ma et al.
J Clin Oncol 2014

TS Lin et al.
J Clin Oncol 2010

W Blum et al.
Haematologica 2010

Similar Publications